{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:19:42Z","timestamp":1791958782757,"version":"4.3.4"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.19452","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T15:10:36Z","timestamp":1602083436000},"page":"e2019452","source":"Crossref","is-referenced-by-count":129,"title":["Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer"],"prefix":"10.1001","volume":"3","author":[{"given":"Stephen E.","family":"Lincoln","sequence":"first","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Stanford University Medical Center, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingshuk","family":"Das","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Michalski","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yang","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu","family":"Ngo","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Blanco","sequence":"additional","affiliation":[{"name":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[{"name":"Invitae Corp, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"issue":"4","key":"zoi200682r3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology.","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"issue":"6","key":"zoi200682r4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"14","key":"zoi200682r5","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jama.2018.2281","article-title":"Sequencing of tumor DNA to guide cancer risk assessment and therapy.","volume":"319","author":"Spencer","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"zoi200682r6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi200682r7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi200682r8","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/annonc\/mdw018","article-title":"Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.","volume":"27","author":"Meric-Bernstam","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi200682r9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi200682r10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jmoldx.2017.09.008","article-title":"Identification of germline variants in tumor genomic sequencing analysis.","volume":"20","author":"Montgomery","year":"2018","journal-title":"J Mol Diagn"},{"issue":"8","key":"zoi200682r12","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focused analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi200682r13","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41436-020-0783-8","article-title":"Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).","volume":"22","author":"Li","year":"2020","journal-title":"Genet Med"},{"key":"zoi200682r15","article-title":"Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing.","author":"Clark","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"zoi200682r16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"zoi200682r17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"issue":"3","key":"zoi200682r18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"5","key":"zoi200682r19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jmoldx.2015.04.009","article-title":"A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients.","volume":"17","author":"Lincoln","year":"2015","journal-title":"J Mol Diagn"},{"issue":"13","key":"zoi200682r20","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer.","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi200682r21","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/gim.2016.58","article-title":"Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing.","volume":"18","author":"Mandelker","year":"2016","journal-title":"Genet Med"},{"issue":"1","key":"zoi200682r22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1809315","article-title":"Genetic variation, comparative genomics, and the diagnosis of disease.","volume":"381","author":"Eichler","year":"2019","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi200682r24","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.","volume":"33","author":"Robson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi200682r25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JOP.19.00201","article-title":"When should tumor genomic profiling prompt consideration of germline testing?","volume":"15","author":"DeLeonardis","year":"2019","journal-title":"J Oncol Pract"},{"key":"zoi200682r23","author":"Lincoln"},{"key":"zoi200682r1","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, ovarian and pancreatic (version 1.2020). Published December 4, 2019. Accessed March 27, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf"},{"key":"zoi200682r2","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: colorectal (version 3.2019). Published December 13, 2019. Accessed March 27, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf"},{"key":"zoi200682r11","unstructured":"National Comprehensive Cancer Network. Prostate cancer (version 1.2020). Published March 16, 2020. Accessed April 9, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"zoi200682r14","unstructured":"National Comprehensive Cancer Network. Non-small cell lung cancer (version 3.2020). Published February 11, 2020. Accessed April 1, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2771398\/lincoln_2020_oi_200682_1626884510.22902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T15:00:46Z","timestamp":1627052446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2771398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.19452","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]}}}